Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 10, 2026

Fortuna Submits Exploitation Permit Application for the Diamba Sud Gold Project, Senegal

View original at globenewswire.com
Fortuna Submits Exploitation Permit Application for the Diamba Sud Gold Project, Senegal VANCOUVER, British Columbia, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fortuna Mining Corp…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Company continues to advance early works and engineering at Diamba Sud, including site preparation activities and detailed engineering programs designed to de-risk critical path activities and support the feasibility study

    80% confidence

  • The updated Mineral Resource estimate will form the basis for the estimation of Mineral Reserves to be used in the feasibility study and will support the evaluation of a potential construction decision targeted for mid-2026

    80% confidence

  • Fortuna plans to publish an updated Mineral Resource estimate for Diamba Sud by the end of the month

    80% confidence

  • We produce gold and silver while creating long-term shared value through efficient production, environmental stewardship, and social responsibility

    80% confidence

  • Robust project economics were demonstrated in the Preliminary Economic Assessment completed in October 2025

    80% confidence

  • Sustainability is at the core of our operations and stakeholder relationships

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Fortuna Submits Exploitation Permit Application for the Diamba Sud Gold Project, Senegal — Source | Via News | ViaNews EU